Skye Bioscience, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SKYE research report →
Companyskyebioscience.com
Skye Bioscience, Inc. , a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension.
- CEO
- Punit S. Dhillon
- IPO
- 2014
- Employees
- 16
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $27.03M
- P/E
- -0.53
- P/S
- 0.00
- P/B
- 3.39
- EV/EBITDA
- -0.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -217.27%
- ROIC
- -651.16%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-55,924,814 · -110.50%
- EPS
- $-1.41 · -93.15%
- Op Income
- $-58,163,565
- FCF YoY
- -60.46%
Performance & Tape
- 52W High
- $5.75
- 52W Low
- $0.57
- 50D MA
- $0.77
- 200D MA
- $1.61
- Beta
- 3.02
- Avg Volume
- 513.25K
Get TickerSpark's AI analysis on SKYE
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 31, 26 | Sharp John P | other | 0 |
| Mar 31, 26 | Smith Karen L. | other | 75,000 |
| Mar 31, 26 | Twitty Christopher | other | 200,000 |
| Mar 31, 26 | Twitty Christopher | other | 150,000 |
| Mar 31, 26 | Twitty Christopher | other | 75,000 |
| Mar 31, 26 | Twitty Christopher | other | 17,004 |
| Mar 31, 26 | Twitty Christopher | other | 12,000 |
| Mar 31, 26 | Twitty Christopher | other | 7,100 |
| Mar 31, 26 | Twitty Christopher | sell | 200,000 |
| Mar 31, 26 | Twitty Christopher | sell | 7,100 |
Our SKYE Coverage
We haven't published any research on SKYE yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SKYE Report →